Research Article
Older Age and Larger Prostate Volume Are Associated with Stress Urinary Incontinence after Plasmakinetic Enucleation of the Prostate
Table 1
Baseline characteristics and perioperative outcomes data of the whole cohort.
| | Variables | Mean ± SD (range) or median (range) or number of patients (%) |
| | Age (yr) | 68.6 ± 7.3 (53–88) | | BMI (kg/m2) | 23.9 ± 3.2 (16.1–38.2) | | Prostate volume (cm3) | 70.1 ± 32.1 (29.1–240.0) | | PSA level (ng/ml) | 5.7 ± 6.9 (0.6–39.2) | | Diabetes | 200 (15.5%) | | Hypertension | 552 (42.9%) | | No. preop treatment (%) | | | Blockers | 592 (46.0%) | | 5-Reductase inhibitor | 659 (51.2%) | | Both | 453 (35.2%) | | International Prostate Symptom Score | | | Voiding symptoms | 15 (5–20) | | Storage symptoms | 14 (1–15) | | Total score | 23 (12–35) | | Quality of life score | 5 (2–6) | | Max flow rate (ml/s) | 6.7 ± 3.2 (0–18) | | Postvoid residual urine (mL) | 126.8 ± 262.2 (0–2000) | | Operation time (min) | 77.7 ± 44.6 (20–240) | | Enucleation time (min) | 18.5 ± 7.5 (10–40) | | Resected weight (g) | 42.4.7 ± 16.1 (17.9–154.5) | | Hospital stay (d) | 4.9 ± 2.0 (3–10) | | Catheter time (d) | 2.1 ± 1.4 (1–7) |
|
|
BMI: body mass index, PSA: prostate specific antigen, No. preop treatment: number with each specific preoperative treatment.
|
